Zydus Lifesciences Ltd. Results

H1FY25 & Q2FY25 Result Announced for Zydus Lifesciences Ltd.

Pharmaceuticals company Zydus Lifesciences announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Revenue from operations at Rs 52,370 million, up 20% over Q2FY24. Research & Development (R&D;) investments for the Q2FY25 stood at Rs 4,800 million (9.2% of revenues). EBITDA for the quarter was Rs 14,614 million, up 28% YoY. EBITDA margin for the quarter stood at 27.9% which is an improvement of 170 bps on a YoY basis. Net Profit for the Q2FY25 was Rs 9,112 million, up 14% YoY. Capex (organic) for the quarter was Rs 3,017 million. H1FY25 Financial Highlights: Revenue from operations at Rs 114,445 million, up 20% over H1FY24. Research & Development (R&D;) investments stood at Rs 8,725 million (7.6% of revenues). EBITDA was Rs 35,454 million, up 34% YoY. EBITDA margin stood at 31%, which is an improvement of 310 bps over H1FY24. Net Profit was Rs 23,311 million, up 24% YoY. Capex (organic) for the half year was Rs 6,031 million. Net Debt to Equity ratio as on 30th September, 2024 was -0.12x while Net Debt to EBITDA stood at -0.41x at the end of H1FY25. Net Cash (negative Net Debt) as on H1FY25 was Rs 25,906 million. Sharvil Patel, Managing Director - Zydus Lifesciences, said: Sustained growth momentum across our businesses along with enhanced profitability drove our strong Q2 performance. Execution success of our differentiated pipeline in the US and outperformance of our India Geography business were particularly noteworthy. With a focus on quality excellence, we will continue to align our processes and strengthen compliance. We are on course to achieve our growth aspirations for FY25 and are committed to investing in sustainable growth initiatives and innovative solutions, keeping patient centricity at the core.

Q1FY25 Quarterly Result Announced for Zydus Lifesciences Ltd.

Pharmaceuticals company Zydus Lifesciences announced Q1FY25 results: Total revenues grew 21% YoY to Rs 62,075 million, led by growth across businesses. India branded formulations business posted double-digit growth and outpaced the market growth both in the chronic and acute segments. Consumer Wellness business delivered an industry leading double-digit growth aided by improved demand scenario and extended summer. US formulations business registered a robust sequential and y-o-y growth driven by new launches and volume expansion in base portfolio. On the international markets front, demand scenario remained strong across key markets and drove the growth. EBITDA margin stood at 33.6%, up 430 bps YoY. Capex (organic) for the quarter: Rs 3,014 million. Net cash: Rs 18,922 million (at 30-Jun’24) vs 8,561 million (at 31-Mar’24)

Q4FY24 Quarterly & FY24 Annual Result Announced for Zydus Lifesciences Ltd.

Pharmaceuticals company Zydus Lifesciences announced Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Revenue from operations was Rs 55,338 million, up 10% over last year. Research & Development (R&D;) investments for the quarter stood at Rs 3,516 million (6.4% of revenues). EBITDA for the quarter was Rs 16,305 million, up 30% YoY. EBITDA margin for the quarter stood at 29.5%, an improvement of 440 bps on a YoY basis. Net Profit for the quarter was Rs 11,823 million, up 299% YoY. Capex (organic) for the quarter was Rs 2,126 million FY24 Financial Highlights: Revenue from operations was Rs 1,95,474 million, up 13% over last year. Research & Development (R&D;) investments stood at Rs 13,096 million (6.7% of revenues). EBITDA was Rs 53,843 million, up 40% YoY. EBITDA margin stood at 27.5%, an improvement of 510 bps over the previous year. Net Profit was Rs 38,595 million, up 97% YoY. Capex (organic) for the year was Rs 8,628 million. Net Debt to Equity ratio as on 31st March, 2024 was -0.04x while Net Debt to EBITDA stood at -0.16x at the end of March, 2024. Net Cash (negative Net Debt) as on March 31st, 2024 was Rs 8,561 million. Dr. Sharvil Patel, Managing Director, said, "We are happy to close the year on a strong note, driven by robust performance across our businesses. Our relentless focus on patient centricity, operational efficiency, strategic investments, and execution of our diversified product portfolio continues to pay off, resulting in a significant improvement in profitability as well. We aspire to sustain strong performance in fiscal year 2024-25 with strong revenue growth and strive to improve EBITDA margins further from FY24 levels. This strong performance is a testament to our commitment to creating long-term value for our stakeholders, and we are wellpositioned for future growth and innovation"

Q3FY24 Quarterly & 9MFY24 Result Announced for Zydus Lifesciences Ltd.

Pharmaceuticals company Zydus Lifesciences announced Q3FY24 & 9MFY24 results: Consolidated Q3FY24: - Revenue from operations stood at Rs 45,052 million, marking a 6% increase from the previous year. - EBITDA for the quarter was reported at Rs 11,024 million, up 15% YoY, with an EBITDA margin of 24.5%, an increase of 200 basis points (bps) YoY. - Research & Development (R&D;) investment was Rs 3,146 million, representing 7.0% of revenues. - The Net Profit for the quarter noted a significant rise of 27% YoY reaching Rs 7,896 million. - Organic capital expenditure (Capex) for the quarter amounted to Rs 2,137 million. Consolidated 9MFY24: - Revenue from operations reached Rs 140,136 million, up by 15% compared to the last year. - EBITDA for 9MFY24 stood at Rs 37,538 million indicating a 44% YoY increase. EBITDA margin was 26.8%, improving by 550 bps over the previous year. - Research & Development (R&D;) investment over nine months was Rs 9,580 million, equivalent to 6.8% of revenues. - Net Profit surged by 61% YoY to Rs 26,772 million. - Organic Capex for the nine months was Rs 6,502 million. Business Segment Performance – Q3FY24 - India Geography: Reported revenue of Rs 18,247 million with an 11% YoY growth. - US Formulations: Registered revenue of Rs 18,427 million, experiencing a slight decline of 4% YoY. - Emerging Markets & Europe Formulations: Noted revenue of Rs 4,937 million, a substantial growth of 31% YoY. - API Business: Revenue was at Rs 1,431 million, down by 24% YoY. - Alliances & Others: Reported a sharp revenue increase of 59% YoY, reaching Rs 395 million. Share Buyback - Zydus Lifesciences announced a share buyback worth Rs 6000 million, representing 0.59% of total outstanding equity shares for Rs 1,005 per share, which is a 25% premium over the closing price as of February 8, 2024. Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, said, "We are pleased with our Q3FY24 performance, particularly with a strong recovery in the domestic formulations business and a resilient US base business. Importantly, our journey of sustained profitability improvement continues and we hope to sustain the same. We are optimistic about our growth prospects driven by a differentiated portfolio in the US, and the continued performance of key brands, well supported by a robust execution engine. We remain on track to end the fiscal year 2024 with a healthy double-digit revenue growth and expect to improve EBITDA margins to 27% plus levels."